For Immediate Releases Chicago, IL – August 9, 2024 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Vertex Pharmaceuticals Incorporated (VRTX) , CRISPR Therapeutics' (CRSP) and Moderna (MRNA) . Here are highlights from Friday's Analyst Blog: Here's How to Play Vertex ( VRTX Quick Quote - Free Report) Stock After Q ...

Table of Contents | --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 19406 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

Vertex, Inc. (NASDAQ:VERX) Q2 2024 Results Conference Call August 7, 2024 8:30 AM ET Company Participants Joe Crivelli - VP, IR David DeStefano - President and CEO John Schwab - CFO Conference Call Participants Brad Reback - Stifel Joshua Reilly - Needham Rob Oliver - Baird Chris Quinter - Morgan Stanley Steve Enders - Citi Daniel Jester - BMO Capital Markets Adam Hotchkiss - Goldman Sachs Alex Sklar - Raymond James Patrick Walravens - Citizens JMP Securities Jake Roberge - William Blair Operator Good morni ...

Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this company would post earnings of $0.13 per share when it actually produced earnings of $0.15, delivering a surprise of 15.38%. Over the last four quarters, the company has surp ...

Exhibit 99.1 Vertex Announces Second Quarter 2024 Financial Results KING OF PRUSSIA, PA – August 7, 2024: Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024. "The second quarter financial results demonstrate the true earnings power of the Vertex business model," stated David DeStefano, Vertex's President, Chief Executive Officer and Chairperson of the Board. "We were GAAP e ...

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a global provider of tax technology solutions, today announced the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing. The closing is pending customary Austrian regulatory approval. The acquisition advances a shared vision to accelerate global commerce and deliver a single, scalable platform for automating business transacti ...

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a global provider of tax technology solutions, today announced the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing. The closing is pending customary Austrian regulatory approval. The acquisition advances a shared vision to accelerate global commerce and deliver a single, scalable platform for automating business transacti ...

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024. "The second quarter financial results demonstrate the true earnings power of the Vertex business model," stated David DeStefano, Vertex's President, Chief Executive Officer and Chairperson of the Board. "We were GAAP earnings positive for the third quarter in a row, g ...

Shares of the rare disease drugmaker are already up more than 40% over the past year. Except for the last several days, the past 12 months have been pretty good for stocks across the board and especially successful for Vertex Pharmaceuticals (VRTX -3.55%). Shares of the biotech stock surged by 42% during the 12 months ended Aug 5. Now that it's already risen a great deal, investors are wondering if they've missed the boat on this stock. Can Vertex Pharmaceuticals stock keep rising in the years ahead or is i ...

Vertex's first loss in years is a big nothingburger. Vertex Pharmaceuticals (VRTX 2.03%) has churned out nice profits quarter after quarter for years. The big biopharmaceutical company's cystic fibrosis (CF) franchise made it easy. However, Vertex announced its second-quarter results following the market close on Thursday. Lo and behold, the company posted a net loss of $3.6 billion, based on generally accepted accounting principles (GAAP). Its non-GAAP loss was $3.3 billion. Should investors worry about th ...